Saturday 17 October 2026
Export JNJ’s income statement to Excel — free account
Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
255.55
2.27
+0.90%
Follow JNJ
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
35.03% | 26.42% | 25.74% | 0.00% | |
Piotroski F-Score |
4 | 4 | 6 | — | |
| 14.13% | 10.66% | 10.67% | 0.00% | ||
ROIC |
20.19% | 16.13% | 15.51% | 0.00% | |
Return on Tangible Assets |
108.66% | 85.09% | 73.92% | 0.00% | |
Average Days of Receivables |
66.57 | 67.12 | 70.99 | 0.00 | |
Free Cash Flow per Share |
8.48 | 7.58 | 9.44 | — | |
Free Cash Flow |
20,418.00 | 18,254.00 | 22,724.00 | — | |
Capital Expenditures |
(4,112.00) | (4,616.00) | (4,884.00) | — | |
| Other line items | |||||
Cash ROIC |
14.47% | 12.97% | 15.88% | — | |
Accounts Receivable Turnover |
5.88 | 5.71 | 5.31 | 0.00 | |
Accounts Payable Turnover |
2.71 | 3.10 | 3.36 | 0.00 | |
Inventory Turnover |
2.27 | 2.28 | 2.20 | 0.00 | |
Average Days of Payables |
144.66 | 123.14 | 107.11 | 0.00 | |
Days of Inventory on Hand |
171.20 | 171.68 | 175.88 | 0.00 | |
Tax Rate |
(0.18) | (0.16) | (0.17) | (0.09) | |
Research and Development Expense of Revenue |
15.57% | 15.53% | 15.42% | 16.19% | |
Selling, General and Administrative Expense of Revenue |
25.14% | 25.53% | 25.67% | 25.67% | |
Share Based Compensation of Revenue |
1.44% | 1.42% | 1.44% | 0.00% | |
Interest Coverage |
35.64 | 25.92 | 26.80 | — | |
Operating CF/Net income |
0.92 | 1.09 | 1.31 | 0.00 | |
Depreciation/Fixed assets |
0.32 | 0.33 | 0.33 | — | |
Capex/Depreciation |
(0.55) | (0.60) | (0.63) | — | |
Revenue per Share |
39.13 | 40.01 | 40.68 | 0.00 | |
Operating CF per Share |
10.19 | 9.49 | 11.47 | — | |
Capex per Share |
(1.71) | (1.92) | (2.03) | — | |
Capex to Sales |
0.04 | 0.05 | 0.05 | 0.00 |
Columns are period end dates · fundamentals updated 14 Oct 2026